Skip to main content

Dake Benjamin T's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Nov 9, 2022

Accession no.
0001415889-22-011245
Filed
Nov 9, 2022
Trade date
Nov 7-8, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 5 derivative transactions. Open-market sales total $474.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dake Benjamin TCIK 0001869248Officer (SEE REMARKS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 7, 2022Common StockMOption exerciseAcquired+2,413$1.74+$4,198.622,413Direct
Nov 7, 2022Common StockMOption exerciseAcquired+15,214$2.14+$32,557.9617,627Direct
Nov 7, 2022Common StockSSaleDisposed−11,122$17.79F2−$197,860.386,505Direct
Nov 7, 2022Common StockSSaleDisposed−3,359$18.58F3−$62,410.223,146Direct
Nov 7, 2022Common StockSSaleDisposed−1,486$19.57F4−$29,081.021,660Direct
Nov 7, 2022Common StockSSaleDisposed−1,660$20.24F5−$33,598.40Direct
Nov 8, 2022Common StockMOption exerciseAcquired+8,373$2.14+$17,918.228,373Direct
Nov 8, 2022Common StockSSaleDisposed−8,373$18.09F6−$151,467.570Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 7, 2022Common StockMOption exerciseDisposed−906$0.00$012,677Direct
Nov 7, 2022Common StockMOption exerciseDisposed−1,507$0.00$031,643Direct
Nov 7, 2022Common StockMOption exerciseDisposed−1,019$0.00$029,533Direct
Nov 7, 2022Common StockMOption exerciseDisposed−14,195$0.00$0284,971Direct
Nov 8, 2022Common StockMOption exerciseDisposed−8,373$0.00$0276,598Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.055 to $18.05, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.07 to $19.01, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.10 to $20.07, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.11 to $20.56, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.555 to $18.510, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

Officer Title: President, Chief Operating Officer and Secretary

Read the full filing on SEC EDGAR (opens in a new tab)